Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Measurement of the toughness of bone: a tutorial with special reference to small animal studies.

Ritchie RO, Koester KJ, Ionova S, Yao W, Lane NE, Ager JW 3rd.

Bone. 2008 Nov;43(5):798-812. doi: 10.1016/j.bone.2008.04.027. Epub 2008 Jun 28. Review. Erratum in: Bone. 2010 Sep;47(3):706.

2.

Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease.

Suva LJ, Hartman E, Dilley JD, Russell S, Akel NS, Skinner RA, Hogue WR, Budde U, Varughese KI, Kanaji T, Ware J.

Am J Pathol. 2008 Feb;172(2):430-9. doi: 10.2353/ajpath.2008.070417. Epub 2008 Jan 10.

3.

Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.

Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, O'Young G, Quon D, Henson M, Damm DL, Muiru GT, Murphy A, Higgins LS, Chakravarty S, Wong DH.

Mol Pharmacol. 2007 Jul;72(1):152-61. Epub 2007 Mar 30.

4.

Inhibin A is an endocrine stimulator of bone mass and strength.

Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, Swain FL, Skinner RA, Hogue WR, Nicks KM, Pierson TM, Suva LJ, Gaddy D.

Endocrinology. 2007 Apr;148(4):1654-65. Epub 2006 Dec 28.

PMID:
17194739
5.

Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.

Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K.

Cell Metab. 2006 Aug;4(2):111-21.

6.

A biomechanical perspective on bone quality.

Hernandez CJ, Keaveny TM.

Bone. 2006 Dec;39(6):1173-81. Epub 2006 Jul 28. Review.

7.

Smad3 deficiency alters key structural elements of the extracellular matrix and mechanotransduction of wound closure.

Arany PR, Flanders KC, Kobayashi T, Kuo CK, Stuelten C, Desai KV, Tuan R, Rennard SI, Roberts AB.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9250-5. Epub 2006 Jun 5.

8.

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS.

Mol Pharmacol. 2006 Aug;70(2):518-31. Epub 2006 May 17.

9.

Regulation of bone mass by Wnt signaling.

Krishnan V, Bryant HU, Macdougald OA.

J Clin Invest. 2006 May;116(5):1202-9. Review.

10.

Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice.

Iida-Klein A, Hughes C, Lu SS, Moreno A, Shen V, Dempster DW, Cosman F, Lindsay R.

J Bone Miner Res. 2006 Feb;21(2):274-82. Epub 2005 Oct 31.

11.

TGF-beta regulates the mechanical properties and composition of bone matrix.

Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, Marshall GW, Marshall SJ, Ritchie RO, Derynck R, Alliston T.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18813-8. Epub 2005 Dec 14.

12.

The relationship between the stiffness and the mineral content of bone.

Currey JD.

J Biomech. 1969 Oct;2(4):477-80. No abstract available.

PMID:
16335147
13.

Current insights into the role of transforming growth factor-beta in bone resorption.

Fox SW, Lovibond AC.

Mol Cell Endocrinol. 2005 Nov 24;243(1-2):19-26. Epub 2005 Oct 10. Review.

PMID:
16219413
14.

Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3.

Kang JS, Alliston T, Delston R, Derynck R.

EMBO J. 2005 Jul 20;24(14):2543-55. Epub 2005 Jun 30.

15.

Global analysis of Smad2/3-dependent TGF-beta signaling in living mice reveals prominent tissue-specific responses to injury.

Lin AH, Luo J, Mondshein LH, ten Dijke P, Vivien D, Contag CH, Wyss-Coray T.

J Immunol. 2005 Jul 1;175(1):547-54.

16.

Transforming growth factor-beta1 to the bone.

Janssens K, ten Dijke P, Janssens S, Van Hul W.

Endocr Rev. 2005 Oct;26(6):743-74. Epub 2005 May 18. Review.

PMID:
15901668
17.

BMP signaling in skeletal development.

Wan M, Cao X.

Biochem Biophys Res Commun. 2005 Mar 18;328(3):651-7. Review.

PMID:
15694398
18.

Development of TGF-beta signalling inhibitors for cancer therapy.

Yingling JM, Blanchard KL, Sawyer JS.

Nat Rev Drug Discov. 2004 Dec;3(12):1011-22. Review.

PMID:
15573100
19.

Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J.

Am J Respir Crit Care Med. 2005 Apr 15;171(8):889-98. Epub 2004 Nov 24.

PMID:
15563636
20.

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.

Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M.

Cancer Res. 2004 Nov 1;64(21):7954-61.

Supplemental Content

Support Center